Currently Recruiting Clinical Trials:

  • JS004-008 (NCT06095583): Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)